Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
|Slideshows|August 31, 2017
Beer: A 12-pack of Health Facts
Author(s)Leo Robert
Growing evidence supports the health benefits of moderate alcohol consumption, but some studies suggest otherwise. Look here for the pros and cons of drinking beer.
Advertisement
Advertisement
Related to this article
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
Advertisement
Advertisement
Trending on Patient Care Online
1
Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions
2
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
3
Why Real-World Evidence Matters for Nonhormonal Menopause VMS Therapy
4
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
5